Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

B cells play an important role in the pathogenesis of systemic lupus erythematosus (SLE), so the safety and activity of anti-B cell immunotherapy with the humanized anti-CD22 antibody epratuzumab was evaluated in SLE patients. An open-label, single-center study of 14 patients with moderately active...

Descripción completa

Detalles Bibliográficos
Autores principales: Dörner, Thomas, Kaufmann, Joerg, Wegener, William A, Teoh, Nick, Goldenberg, David M, Burmester, Gerd R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526638/
https://www.ncbi.nlm.nih.gov/pubmed/16630358
http://dx.doi.org/10.1186/ar1942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1526638/
https://www.ncbi.nlm.nih.gov/pubmed/16630358
http://dx.doi.org/10.1186/ar1942

Ejemplares similares